Cargando…

Molecular Pathways in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and consequent right ventricular dysfunction. Exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Aangi J., Vorla, Mounica, Kalra, Dinesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456336/
https://www.ncbi.nlm.nih.gov/pubmed/36077398
http://dx.doi.org/10.3390/ijms231710001
_version_ 1784785791049793536
author Shah, Aangi J.
Vorla, Mounica
Kalra, Dinesh K.
author_facet Shah, Aangi J.
Vorla, Mounica
Kalra, Dinesh K.
author_sort Shah, Aangi J.
collection PubMed
description Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and consequent right ventricular dysfunction. Existing treatments target limited pathways with only modest improvement in disease morbidity, and little or no improvement in mortality. Ongoing research has focused on the molecular basis of pulmonary arterial hypertension and is going to be important in the discovery of new treatments and genetic pathways involved. This review focuses on the molecular pathogenesis of pulmonary arterial hypertension.
format Online
Article
Text
id pubmed-9456336
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94563362022-09-09 Molecular Pathways in Pulmonary Arterial Hypertension Shah, Aangi J. Vorla, Mounica Kalra, Dinesh K. Int J Mol Sci Review Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and consequent right ventricular dysfunction. Existing treatments target limited pathways with only modest improvement in disease morbidity, and little or no improvement in mortality. Ongoing research has focused on the molecular basis of pulmonary arterial hypertension and is going to be important in the discovery of new treatments and genetic pathways involved. This review focuses on the molecular pathogenesis of pulmonary arterial hypertension. MDPI 2022-09-02 /pmc/articles/PMC9456336/ /pubmed/36077398 http://dx.doi.org/10.3390/ijms231710001 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shah, Aangi J.
Vorla, Mounica
Kalra, Dinesh K.
Molecular Pathways in Pulmonary Arterial Hypertension
title Molecular Pathways in Pulmonary Arterial Hypertension
title_full Molecular Pathways in Pulmonary Arterial Hypertension
title_fullStr Molecular Pathways in Pulmonary Arterial Hypertension
title_full_unstemmed Molecular Pathways in Pulmonary Arterial Hypertension
title_short Molecular Pathways in Pulmonary Arterial Hypertension
title_sort molecular pathways in pulmonary arterial hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456336/
https://www.ncbi.nlm.nih.gov/pubmed/36077398
http://dx.doi.org/10.3390/ijms231710001
work_keys_str_mv AT shahaangij molecularpathwaysinpulmonaryarterialhypertension
AT vorlamounica molecularpathwaysinpulmonaryarterialhypertension
AT kalradineshk molecularpathwaysinpulmonaryarterialhypertension